The healthcare community is excited by retatrutide, a novel dual GIP and GLP-1 agonist that’s showing remarkable results in early studies . This treatment works by mimicking natural hormones to affect appetite and increase feelings of satisfaction , ultimately leading noticeable weight decrease. While currently under investigation and not broadly